AI Article Synopsis
- CAR T-cell therapy has shown promise as a treatment for central nervous system (CNS) lymphomas, despite previous concerns about neurotoxicity.
- Recent studies report high response rates in patients with CNS lymphomas, with complete response rates between 32% and 67%, and one-year progression-free survival (PFS) of 40% to 60%.
- Although neurotoxicity affects a significant percentage of patients (36% to 68%), the levels of severe neurotoxicity are relatively low (4.5% to 29%), indicating that CAR T-cell therapy could be a viable option for CNS lymphomas moving forward.
Article Abstract
Purpose Of Review: While anti-CD19 CAR T-cell therapy represents a major advance in systemic diffuse large B-cell lymphomas, central nervous system (CNS) lymphomas have been excluded from pivotal trials because of the fear of neurotoxicity. The purpose of this review was to assess the efficacy and tolerance of CAR T-cells in CNS lymphomas based on recently published studies.
Recent Findings: All the studies on CAR T-cell therapy for both primary and secondary CNS lymphomas reported high response rates (complete response rates ranging from 32 to 67%) in highly pre-treated patients. One-year PFS reached 40 to 60% in several studies. Neurotoxicity occurred in 36 to 68% of patients, including grade 3-4 neurotoxicity in 4.5 to 29% of patients. CAR T-cell therapy appears to be a very promising treatment in CNS lymphomas, with efficacy results close to those observed in systemic lymphomas. The toxicity profile, notably regarding neurotoxicity, is reassuring and should not prevent the development of CAR T-cells in the disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11912-024-01609-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!